References
- ZhangJNieSWangSNanoencapsulation enhances epigallocatechin-3-gallate stability and its antiatherogenic bioactivities in macrophagesJ Agric Food Chem201361389200920924020822
- FangueiroJFAndreaniTFernandesLPhysicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillationColloids Surf B Biointerfaces201412345246025303852
- LeuJGChenSAChenHMThe effects of gold nanoparticles in wound healing with antioxidant epigallocatechin gallate and α-lipoic acidNanomedicine20128576777521906577
- SmithAGiuntaBBickfordPCFountainMTanJShytleRDNanolipidic particles improve the bioavailability and α-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer’s diseaseInt J Pharm20103891–220721220083179
- WangDTaylorEWWangYWanXZhangJEncapsulated nanoepigallocatechin-3-gallate and elemental selenium nanoparticles as paradigms for nanochemopreventionInt J Nanomedicine201271711172122619522
- DoktorovovaSSoutoEBSilvaAMNanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers – a systematic review of in vitro dataEur J Pharm Biopharm201487111824530885
- MullerRHRadtkeMWissingSASolid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparationsAdv Drug Deliv Rev200254Suppl 1S131S15512460720
- MullerRHMaderKGohlaSSolid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the artEur J Pharm Biopharm200050116117710840199
- MullerRHKeckCMChallenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticlesJ Biotechnol20041131–315117015380654
- NevesARLucioMMartinsSLimaJLReisSNovel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailabilityInt J Nanomedicine2013817718723326193
- DanhierFLecouturierNVromanBPaclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluationJ Control Release20091331111718950666
- ArturssonPKarlssonJCorrelation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cellsBiochem Biophys Res Commun199117538808851673839
- ArturssonPPalmKLuthmanKCaco-2 monolayers in experimental and theoretical predictions of drug transportAdv Drug Deliv Rev2001461–3274311259831
- ShahPJoganiVBagchiTMisraARole of Caco-2 cell monolayers in prediction of intestinal drug absorptionBiotechnol Prog200622118619816454510
- CortiGMaestrelliFCirriMZerroukNMuraPDevelopment and evaluation of an in vitro method for prediction of human drug absorption II. Demonstration of the method suitabilityEur J Pharm Sci200627435436216364612
- MüllerHJacobsCKayserONanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the futureAdv Drug Deliv Rev200147131911251242
- SunYHungWCChenFYLeeCCHuangHWInteraction of tea catechin (-)-epigallocatechin gallate with lipid bilayersBiophys J20099631026103519186140
- SmithTJGreen Tea Polyphenols in drug discovery – a success or failure?Expert Opin Drug Discov20116658959521731575
- ShahidiHNutraceuticals, functional foods and dietary supplements in health and diseaseJ Food Drug Anal201220226230
- MerelesDHunsteinWEpigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls than promises?Int J Mol Sci20111295592560322016611
- YangCSWangHCancer therapy combination: green tea and a phosphodiesterase 5 inhibitor?J Clin Invest2013123255655823348734
- FengWHwangHSKryshtalDOCoordinated regulation of murine cardiomyocyte contractility by nanomolar (-)-epigallocatechin-3-gallate, the major green tea catechinMol Pharmacol2012825993100022918967